NCT00906451

Brief Summary

During myocardial infarction, inflammatory response may negatively influence ventricle wall remodeling as well as endothelium-dependent vasomotor function in the coronary and systemic arterial systems. Statins have been consistently proved to attenuate inflammation and improve endothelial function. In this study, we tested the effect of different doses of statin on inflammatory response and endothelium-dependent vasodilation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Nov 2008

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2008

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2009

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

May 19, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 21, 2009

Completed
Last Updated

June 23, 2011

Status Verified

May 1, 2009

Enrollment Period

6 months

First QC Date

May 19, 2009

Last Update Submit

June 21, 2011

Conditions

Keywords

myocardial infarctioninflammationendothelial dysfunction

Outcome Measures

Primary Outcomes (1)

  • Elevation of plasma C reactive protein

    Changes in CRP levels between the first and fifth day after myocardial infarction

    Five days

Secondary Outcomes (1)

  • Brachial Artery Endothelial function

    30 days

Study Arms (4)

No lipid-lowering

NO INTERVENTION

No lipid-lowering treatment during the first 7 days and then simvastatin 20 mg/day for three additional weeks, till the endothelial function assessment

Drug: Simvastatin

Simvastatin 20 mg

EXPERIMENTAL

Simvastatin 20 mg/day for 30 days, till the endothelial function assessment

Drug: Simvastatin

Simvastatin 40 mg

EXPERIMENTAL

Simvastatin 40 mg/day for 7 days and then switched to simvastatin 20mg/day for additional 3 weeks, till the endothelial function assessment

Drug: Simvastatin

Simvastatin 80 mg

EXPERIMENTAL

Simvastatin 80 mg/day for 7 days and then switched to simvastatin 20 mg/day for additional 3 weeks, till the endothelial function assessment

Drug: Simvastatin

Interventions

Simvastatin

No lipid-loweringSimvastatin 20 mgSimvastatin 40 mgSimvastatin 80 mg

Eligibility Criteria

Age45 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Less than 24 hours after the onset of MI symptoms
  • ST-segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal plane) in two contiguous leads
  • Myocardial necrosis, as evidenced by increased CK-MB and troponin levels

You may not qualify if:

  • Use of statins for at least 6 months prior the myocardial infarction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital de Base do Distrito Federal

Brasília, Federal District, 70000000, Brazil

Location

Related Publications (1)

  • Sposito AC, Santos SN, de Faria EC, Abdalla DS, da Silva LP, Soares AA, Japiassu AV, Quinaglia e Silva JC, Ramires JA, Coelho OR. Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction. Arterioscler Thromb Vasc Biol. 2011 May;31(5):1240-6. doi: 10.1161/ATVBAHA.110.218685. Epub 2011 Mar 3.

MeSH Terms

Conditions

Myocardial InfarctionInflammation

Interventions

Simvastatin

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Intervention Hierarchy (Ancestors)

LovastatinNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic Compounds

Study Officials

  • Andrei C Sposito, MD, PhD

    University of Brasilia Medical School

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 19, 2009

First Posted

May 21, 2009

Study Start

November 1, 2008

Primary Completion

May 1, 2009

Study Completion

May 1, 2009

Last Updated

June 23, 2011

Record last verified: 2009-05

Locations